| [1] |
Huang TE, Deng YN, Hsu JL, et al. Evaluation of the anticancer activity of a bile acid-dihydroartemisinin hybrid ursodeoxycholic-dihydroartemisinin in hepatocellular carcinoma cells[J]. Front Pharmacol, 2020(11):599067.
|
| [2] |
Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2019, 5(12):1749-1768.
|
| [3] |
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
|
| [4] |
Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation[J]. Abdominal Imaging, 2011, 36(3):232-243.
|
| [5] |
Aihara T, Noguchi S, Sasaki Y, et al. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis[J]. Gastroenterology, 1994, 107(6):1805-1811.
|
| [6] |
Park YN. Update on precursor and early lesions of hepatocellular carcinomas[J]. Arch Pathol Lab Med, 2011, 135(6):704-715.
|
| [7] |
International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia[J]. Hepatology, 2009, 49(2):658-664.
|
| [8] |
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12):2214-2229.
|
| [9] |
Hsia CY, Huo TI, Chiang SY，et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma[J]. Eur J Surg Oncol, 2007, 33(2):208-212.
|
| [10] |
Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis[J]. Clin Chim Acta, 2013(425):212-220.
|
| [11] |
Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs[J]. Nat Commun, 2016(7):11215.
|
| [12] |
Ren S, Xin Z, Xu Y, et al. Construction and analysis of circular RNA molecular regulatory networks in liver cancer[J]. Cell Cycle, 2017, 16(22):2204-2211.
|
| [13] |
王婷, 吴文晓, 马全涛, 等. 肝癌早期诊断标志物的研究进展[J]. 中国药事, 2020, 34(3):349-356.
|
| [14] |
Xing H, Zheng YJ, Han J, et al. Protein induced by vitamin K absence or antagonist-Ⅱ versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a systematic review with meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(6):487-495.
|
| [15] |
国家卫生健康委员会. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2):277-292.
|
| [16] |
Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma[J]. Z Gastroenterol, 2016, 54(12):1296-1305.
|
| [17] |
Xu WJ, Guo BL, Han YG, et al. Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels[J]. Tumor Biol, 2014, 35(12):12069-12074.
|
| [18] |
刘毓键, 马明洋. 血清标志物在肝细胞肝癌早期诊断中的研究进展及应用前景[J]. 医学综述, 2020, 26(7):1325-1330, 1336.
|
| [19] |
Xu D, Su C, Sun L, et al. Performance of serum glypican 3 in diagnosis of hepatocellular carcinoma: a meta-analysis[J]. Ann Hepatol, 2019, 18(1):58-67.
|
| [20] |
Zhu M, Zheng J, Wu F, et al. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis[J]. J Med Virol, 2020, DOI: 10.1002/jmv.25704[Epub ahead of print].
|
| [21] |
Fezza M, Moussa M, Aoun R, et al. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: implication of TGF-β1[J]. PLoS One, 2019, 14(9):e0223252.
|
| [22] |
Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study[J]. Lancet Oncol, 2012, 13(8):817-826.
|
| [23] |
Zhou J，Yu L，Gao X，et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol，2011，29(36):4781-4788.
|
| [24] |
Peng C, Ye Y, Wang Z, et al. Circulating microRNAs for the diagnosis of hepatocellular carcinoma[J]. Dig Liver Dis, 2019, 51(5):621-631.
|
| [25] |
Peng W, Fan H. Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma[J]. Biomed Pharmacother, 2015(72):113-118.
|
| [26] |
El-Tawdi AH, Matboli M, El-Nakeep S, et al. Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(7):869-877.
|
| [27] |
Yuan W, Sun Y, Liu L, et al. Circulating lncRNAs serve as diagnostic markers for hepatocellular carcinoma[J]. Cell Physiol Biochem, 2017, 44(1):125-132.
|
| [28] |
Ignatiadis M, Dawson SJ. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?[J]. Ann Oncol, 2014, 25(12):2304-2313.
|
| [29] |
Huang A，Zhang X，Zhou SL，et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity[J]. J Cancer，2016，7(13):1907-1914.
|
| [30] |
Huang A，Zhao X，Yang XR，et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J]. J Hepatol，2017，67(2):293-301.
|
| [31] |
Wen L，Li J，Guo H，et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients[J]. Cell Res，2015，25(11):1250-1264.
|
| [32] |
Xu RH，Wei W，Krawczyk M，et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11):1155-1161.
|
| [33] |
Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut, 2019, 68(12):2195-2205.
|
| [34] |
Sepideh A, Karim P, Hossein A, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial[J]. J Am Coll Nutr, 2016, 35(6):500-505.
|
| [35] |
Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut, 2019, 68(6):1014-1023.
|
| [36] |
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2012, 57(1):69-76.
|
| [37] |
Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging[J]. Eur Radiol, 2011, 21(10):2056-2066.
|
| [38] |
Bota S, Piscaglia F, Marinelli S, et al. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma[J]. Liver Cancer, 2012, 1(3/4):190-200.
|
| [39] |
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4):908-943.
|
| [40] |
Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis[J]. Gut, 2010, 59(5):638-644.
|
| [41] |
Okada M, Imai Y, Kim T, et al. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging[J]. J Magn Reson Imaging, 2010, 32(4):903-913.
|
| [42] |
Lee DH, Lee JM, Baek JH, et al. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings[J]. Radiology, 2015, 274(1):149-160.
|
| [43] |
Kim YS, Song JS, Lee HK, et al. Hypovascular hypointense nodules on hepatobiliary phase without T2 hyperintensity on gadoxetic acid-enhanced MR images in patients with chronic liver disease: long-term outcomes and risk factors for hypervascular transformation[J]. Eur Radiol, 2016, 26(10):3728-3736.
|
| [44] |
Park MS, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients[J]. Hepatology, 2012, 56(1):140-148.
|